-
Prophylaxis of migraine and cluster headaches
(Not for acute treatment of migraine attacks)
Dosage:
-
Adults:
Initial: 0.5 mg at night
Maintenance: 1.5 mg daily (can be divided into 2–3 doses)
Max: 3 mg/day -
Children (>2 years):
Starting dose: 0.25–0.5 mg at night
Max: 1.5 mg/day, divided into 2–3 doses
-
Tablets: 0.5 mg
-
Some formulations may include 1.5 mg sustained-release tablets in certain markets
-
Usually taken at night to minimize drowsiness
-
Can be taken with or without food
-
Do not exceed prescribed dose
-
Gradual titration helps minimize side effects like drowsiness
-
Class: Serotonin (5-HT2) receptor antagonist with antihistaminic and anticholinergic properties
-
Mechanism: ➤ Inhibits serotonin (5-HT) and histamine receptors
➤ Prevents vasodilation and vascular permeability associated with migraines -
Also has a weak anticholinergic and sedative effect
Common:
-
Drowsiness or sedation
-
Increased appetite
-
Weight gain
-
Dry mouth
-
Dizziness
Less Common:
-
Nausea
-
Fatigue
-
Anxiety
-
Rash
-
Hypersensitivity to pizotifen or excipients
-
Angle-closure glaucoma
-
Urinary retention, especially due to prostatic hypertrophy
-
CNS depressants (e.g., alcohol, sedatives):
➤ Increased sedative effect -
MAO inhibitors:
➤ Avoid concurrent use (risk of hypertensive crisis or serotonin syndrome)
Drug Status
Availability | |
Pregnancy | |
Breastfeeding | |
Schedule |
BRAND NAME | STRENGTH | FORMULATION | PACK SIZE | MANUFACTURER | DISTRIBUTOR |
---|---|---|---|---|---|
Mosegor | 0.5mg/10mL | Suspension | 100mL | Novartis Pharma | Novartis Kenya |